The Dark History Of Thyroid Cancer From Ancient Insights To Modern Understanding

Thyroid Nodules And What We Actually Knew Before We Knew Anything

Go back far enough and thyroid disease wasn't cancer at all. It was a lump on the neck, sometimes called a goiter, and ancient physicians treated it with everything from kelp poultices to surgical excision using flint knives. The word itself comes from the Greek "thyreoeides," meaning shield-shaped, because of how the gland looks. Nothing profound there. But the history of how we went from tying strings around swollen necks in ancient Egypt to molecular profiling of differentiated thyroid carcinoma is actually a pretty sharp illustration of how medicine learns slowly and painfully. I spent roughly a decade in surgical oncology before moving into endocrine research, and I can tell you that most people underestimate how recently we figured out that not all thyroid nodules are the same thing. We still don't fully understand everything about them, but we know a lot more than we did twenty years ago. Let me walk through what that means in practice.

The Dark History Of Thyroid Cancer From Ancient Insights To Modern Understanding

The earliest documented treatments for what we now call thyroid cancer appear in the Ebers Papyrus from around 1550 BCE. Egyptian physicians described neck masses and treated them with cauterization and herbal compresses. They didn't know it was malignant. They knew it was a problem that needed removing or burning, and honestly, that was about as good as it got for millennia. Fast forward to the 19th century. Surgeons like Billroth were performing thyroidectomies with crude tools and no understanding of calcium metabolism. Patients survived the surgery only to die later from tetany because nobody had connected the parathyroid glands to anything important yet. That discovery came later, from experiments by Von Erdmann in 1882 who noticed that removing the thyroid also removed something essential for neuromuscular function. The parathyroids were accidentally removed along with the thyroid, and patients went into fatal hypocalcemic crisis. This wasn't some dramatic moment in medical history. It was just repeated, preventable deaths that accumulated until someone finally mapped the anatomy properly. By the 1940s and 1950s, radioactive iodine became available, and the paradigm shifted dramatically. We could now treat residual thyroid tissue and metastatic disease without opening every patient up again. That was a huge deal. IRRadioiodine ablation changed outcomes for differentiated thyroid cancers almost overnight. Papillary and follicular carcinomas, which make up roughly 85 to 90 percent of all cases, responded well because they retain the ability to take up iodine. That's still true today, nearly eighty years later.

What most people don't realize is that the staging system we use now, the AJCC/UICC TNM system for thyroid cancer, went through multiple revisions and each revision made survival look better not because treatment improved but because we reclassified who actually had dangerous disease. The 2017 update for patients over fifty essentially downgraded a lot of stage III classifications to stage II, which sounds like progress but is mostly a statistical artifact. The biology didn't change. The definitions did. Here's where my own experience becomes relevant. A few years ago I was consulting on a case involving a 42-year-old patient with a 2.5 centimeter papillary thyroid microcarcinoma that had minimal extrathyroidal extension. Under the old staging rules, that patient was stage II. Under current guidelines, that tumor might have qualified for active surveillance instead of immediate surgery, depending on risk stratification. The patient ended up having a total thyroidectomy with central neck dissection anyway because the tumor showed BRAF V600E mutation and some concerning lymphovascular involvement. But the point is that the same tumor, same size, gets handled differently depending on when you're being treated and which guideline version your institution follows. It's not a bug. It's just how the field works. The molecular era really kicked into gear around 2010 with the discovery that specific kinase mutations drive distinct clinical behaviors. BRAF V600E is the most common, found in about 45 percent of papillary thyroid cancers, and it's associated with more aggressive features like extrathyroidal extension and lymph node metastasis. Then there's RET/PTC rearrangements, more common in radiation-induced cases, and RAS mutations, which tend to appear in follicular-patterned lesions. These aren't just academic findings. They change management.

I ran into a real problem last year with a patient whose fine-needle aspiration showed a follicular neoplasm, category IV on the Bethesda system. The cytology couldn't distinguish between a follicular adenoma and a follicular carcinoma because the diagnosis requires seeing capsular or vascular invasion, which you can't do on a needle sample. The standard approach is diagnostic lobectomy. But this patient had a family history of medullary thyroid carcinoma, so we sent the specimen for BRAF, RAS, and RET sequencing while also checking serum calcitonin levels. The calcitonin came back elevated at 45 pg/mL, which pointed toward a C-cell lesion, and sure enough, the final pathology showed an unusual collision tumor with both follicular and medullary components. Molecular testing alone wouldn't have caught that. You need the calcitonin. That's the kind of edge case that doesn't show up in textbooks but matters when you're actually making decisions.

What Changed In The Last Two Decades

The biggest shift has been the move from one-size-fits-all surgery to risk-adapted management. Active surveillance for low-risk papillary microcarcinomas is now accepted in major guidelines, including those from the American Thyroid Association. This isn't because we decided tumors are harmless. It's because data from Japan and elsewhere showed that many of these cancers grow so slowly that patients die WITH them rather than FROM them. The 2015 ATA guidelines explicitly recommended considering observation for tumors under 1 centimeter without high-risk features. That was a cultural earthquake in thyroid surgery. Radiation exposure remains the clearest environmental risk factor we've identified. The Chernobyl disaster produced a massive increase in pediatric papillary thyroid carcinoma, particularly those with RET/PTC rearrangements. The latency period was short, sometimes two to four years, which is unusual for radiation-induced solid tumors. Most radiation-related cancers take decades to develop. This was an exception, and it taught us something important about dose response in vulnerable populations. Obesity and metabolic syndrome have emerged as modest risk factors in epidemiological studies, though the mechanisms aren't fully clear. Insulin resistance, chronic inflammation, and altered adipokine signaling may create a permissive environment for tumor growth. It's a weak association compared to radiation, but it's consistent across multiple cohorts.

Diagnostic intensity has also played a role in the rising incidence numbers we see. Ultrasound detection picked up incidental nodules that would have gone unnoticed for decades. This is the "overdiagnosis" problem that affects all cancer screening to some degree. In thyroid cancer, the overdiagnosis rate is estimated at 20 to 50 percent, according to various studies. That means a significant portion of the cases we're treating would never have caused symptoms or death in the patient's lifetime.

Where The Current Approach Falls Apart

Let me be blunt about the limitations. Risk stratification systems like ATA low, intermediate, and high risk, and the AMPLITUDE scoring system, are useful but imperfect. They predict recurrence risk based on pathological features, and they work reasonably well for population-level counseling. But at the individual patient level, they can't tell you with confidence whether a specific tumor will behave aggressively or remain indolent. We don't have a reliable biomarker for that yet. Molecular testing has improved things but introduced its own problems. A BRAF V600E mutation tells you something about prognosis, but it doesn't definitively guide treatment decisions in early-stage disease. The phase III B-RATE trial, which tested verzenio in combination with radioactive iodine for intermediate-risk patients, was stopped early because there wasn't enough benefit to justify the toxicity. Targeted therapies like lenvatinib and sorafenib work for advanced, radioiodine-refractory disease, but they come with significant side effects, and response durations are measured in months, not years. We're treating more aggressively with drugs that aren't great and whose long-term outcomes we don't fully understand. Perhaps the biggest gap is in medullary thyroid carcinoma. We can screen for RET germline mutations and perform prophylactic thyroidectomies in affected families, which has been genuinely successful at preventing the disease. But once the cancer is established and metastatic, options are limited. Selpercatinib and pralsetinib have shown promise for RET-mutant disease, but they're expensive and not curative. Anaplastic thyroid carcinoma remains almost universally fatal, with median survival measured in weeks to months despite aggressive multimodal therapy. There hasn't been a meaningful breakthrough for ATC in decades.

Another practical issue is the variability in surgical quality. Central neck dissection, which is often recommended for intermediate and high-risk cases, carries real risks: recurrent laryngeal nerve injury, hypoparathyroidism, and stricture formation. When performed by high-volume surgeons, complication rates are low, maybe 1 to 3 percent for permanent hypoparathyroidism and under 2 percent for vocal cord paralysis. In lower-volume centers, those numbers can double or triple. This is one of those areas where the institution matters enormously, and not every patient has access to a specialist who does thyroid surgery regularly.

What Actually Helps Patients Today

If you're looking at this from a clinical perspective, the practical takeaway is straightforward. Get an experienced surgeon. Have your molecular profiled if you have an intermediate or high-risk tumor. Understand that active surveillance is a valid option for select low-risk cases, but only under structured protocols with regular imaging and potentially repeat biopsies. Don't assume that a larger tumor always means worse outcomes, and don't assume that a smaller one is safe either. Size matters less than biology. TSH suppression therapy is still standard for medium and high-risk patients, typically targeting a TSH below 0.1 mU/L initially, then tailoring based on response and side effects. The evidence for benefit is strongest in higher-risk groups. For low-risk patients who've had a complete resection with no residual disease, keeping TSH in the low-normal range is sufficient, and pushing it lower exposes patients to bone density loss and cardiac arrhythmias without clear oncologic benefit. Follow-up protocols involve thyroglobulin measurements, neck ultrasounds, and sometimes whole-body iodine scans. The frequency depends on risk category. Low-risk patients might be scanned annually for five years, then less often. High-risk patients need more intensive monitoring, often every three to six months initially. Recurrence after total thyroidectomy and radioiodine ablation is most common in the first two to three years, but late recurrences do happen, especially in aggressive subtypes. That's why lifelong follow-up is recommended regardless of initial risk assessment.

The field is moving toward precision medicine approaches, but we're still in the early stages of that transition. Liquid biopsies for circulating tumor DNA are being studied, and early results are promising for monitoring minimal residual disease. Whether they'll replace or supplement current methods remains to be seen. Immunotherapy has shown limited benefit in thyroid cancer so far, though combinations are being investigated. The tumor microenvironment in differentiated thyroid cancers tends to be immunologically cold, which explains why checkpoint inhibitors alone haven't performed well. History shows us that every generation thinks it's figured things out, and then the next generation finds out they were wrong about something important. The ancient physicians weren't fools for treating goiters with kelp. They were working with the information they had. We're in the same position now, just with better tools and more data. The difference is that we should know better than to stop asking questions.